drugset / Trial / NCT06717022
A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors
Recruiting
24 enrolled
Tianjin Medical University Cancer Institute and Hospital
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.
Timeline
- Start
- 2024-05-06
- Primary completion
- 2026-06
- Completion
- 2039-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CHT102 | Cell therapy | 2.5e+06 cells/kg | Other |
| Subject | CHT102 | Cell therapy | 5e+06 cells/kg | Other |
| Subject | CHT102 | Cell therapy | 1e+07 cells/kg | Other |
| Subject | CHT102 | Cell therapy | 2e+07 cells/kg | Other |
| Subject | CHT102 | Cell therapy | 3e+07 cells/kg | Other |